TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) was the recipient of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 20,535 shares, a growth of 70.4% from the July 30th total of 12,050 shares. Based on an average daily trading volume, of 3,313 shares, the short-interest ratio is presently 6.2 days.
Institutional Investors Weigh In On TriSalus Life Sciences
Hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC lifted its position in TriSalus Life Sciences by 439.0% during the third quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock worth $199,000 after buying an additional 103,336 shares during the period. Cerity Partners LLC purchased a new stake in shares of TriSalus Life Sciences during the fourth quarter worth about $1,374,000. Fort Baker Capital Management LP acquired a new stake in shares of TriSalus Life Sciences during the fourth quarter worth approximately $44,000. Finally, Aristeia Capital L.L.C. acquired a new stake in TriSalus Life Sciences during the fourth quarter valued at approximately $43,000.
TriSalus Life Sciences Price Performance
NASDAQ TLSIW traded up $0.02 on Tuesday, reaching $0.89. The stock had a trading volume of 384 shares, compared to its average volume of 5,208. The business’s 50-day moving average price is $0.86 and its 200 day moving average price is $0.95. TriSalus Life Sciences has a 12-month low of $0.44 and a 12-month high of $2.19.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.
Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.
See Also
- Five stocks we like better than TriSalus Life Sciences
- Cook Out, Silicon In: Will Ternus Trigger Apple’s Edge AI Boom?
- Qualcomm’s AI Ambitions Run Into a Smartphone Reality Check
- Palantir’s Sovereign AI Pitch Tests Microsoft’s Cloud-First AI Bet
- Salesforce Looks Overbought, But the Rally May Be Far From Over
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
